MedTrace Logo

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

NCT02730377 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1991

Last updated 2020-07-07

Study results available
· View outcomes & findings →

Summary

This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

liraglutide

Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

DRUG

alpha-glucosidase inhibitors

Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

DRUG

DPP-4 inhibitors

Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

DRUG

meglitinides

Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

DRUG

SGLT-2 inhibitors

Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

DRUG

sulphonylurea

Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

DRUG

thiazolidinediones

Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-28
Primary Completion
2019-08-05
Completion
2019-08-12
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Colombia
  • India
  • Latvia
  • Lebanon
  • Puerto Rico
  • Russia
  • Serbia
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02730377 on ClinicalTrials.gov